This capital increase will enable the Company to have adequate financial capacity adapted to its growth
strategy and improve its worldwide unique technological platform.
BioProtein Technologies intends to become the undisputed leader in the production of recombinant proteins
in the milk of transgenic rabbits and is currently working on the development of an innovative biological
drug in the prevention or treatment of the septic shock.
Jouy-en-Josas, France – April 28, 2010 – BioProtein Technologies, the biotechnology company specialized in
the production of therapeutic proteins in the milk of transgenic rabbits, announced today the
reinforcement of its capital base with a 0.52 Million Euros raised from its historical shareholders.
In order to achieve this fundraise, BioProtein was able to lean on the trust and support of its original
shareholders. The Company has raised nearly 11Million Euros since its foundation in 1998.
Following on from the success in the production of recombinant proteins in part for internal projects or
programs conducted in collaboration with various pharmaceutical and biotechnology companies,
BioProtein intends to develop its growth and expand its commercial offer.
Alexandre Fouassier, COO of BioProtein Technologies, declared: "We are delighted to have completed this
capital increase with our shareholders who maintain their historical support and confidence in the
development of BioProtein, allowing us to improve our growth. With this strengthening of our capital, we will
continue to develop our technology platform and reinforce our expertise in the fields of molecular biology
and embryology. We are currently developing optimized transgenic strains enabling us to produce more
efficiently complex glycosylated protein or recombinant vaccines in the milk of transgenic rabbits.
BioProtein develops genetically improved strains for the quality of proteins produced (especially
glycosylation) and also strains producing less natural milk proteins, thus facilitating the purification steps of a
therapeutic protein of interest from the milk.
We are also working on the development of a proprietary therapeutic protein in the prevention and
treatment of the septic shock. This phenomenon also called endotoxic shock consists in a severe multiorgan
failure triggered by an inflammatory reaction of the body due to a bacterial infection. It is the
leading cause of death in intensive care units with a high morbidity rate of 25 to 40%. The therapeutic
options are very limited in this indication, while the number of cases of septic shock has amplified in recent
decades, mainly due to the increased number of invasive medical interventions on ever more aged
patients.
About BioProtein Technologies (BPT)
BioProtein Technologies is the world leader in the production of recombinant proteins in the milk of
transgenic rabbits. The Company’s unique contract manufacturing capabilities have been designed to
meet the increasing demands of the pharmaceutical and the biotechnology industries for therapeutic
protein production. Rabbits offer great advantages in terms of scale-up and time-to-market and can
produce up to 10-15 liters of milk per year. From the annual production of few hundred rabbits, several
kilograms of protein can be isolated and purified to a very high quality.
BioProtein Technologies has strong expertise through the entire manufacturing process from genes or cDNA
expression to animal production and milking. The Company has produced complex and difficult-to-express
proteins, including monoclonal antibodies, plasma proteins, hormones and vaccinating antigens, all of
which demonstrates BioProtein Technologies’ ability to fulfill the most rigorous specifications in protein
production.
For more information please visit: www.bioprotein.com
